Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.59 |
| ▸ | ESR2 known ✓ | Q92731 | 13/20 | 0.59 |
| ▸ | TOP1 known ✓ | P11387 | 2/20 | 0.59 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HRAS | P01112 | 14/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7531843 | 1.00 | KDM4E (0.61) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL6775903 | 0.90 | KDM4E (0.52) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL9124388 | 0.89 | KDM4E (0.76) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL10688614 | 0.89 | KDM4E (0.76) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL6548715 | 0.89 | KDM4E (0.76) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL7539937 | 0.88 | KDM4E (0.56) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL7533970 | 0.88 | KDM4E (0.56) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7510361 | 0.88 | HRAS (0.76) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL7532883 | 0.87 | KDM4E (0.55) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL6175427 | 0.87 | KDM4E (0.62) | KDM4EPOLBMAPTHIF1AHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951951-B2 | Process for preparing distamycin derivatives | PHARMACIA ITALIA S.P.A. (IT) | 2005-10-04 | — | — | US | disclosed |
| EP-1064281-B1 | BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-05-25 | — | — | EP | disclosed |
| US-6753316-B1 | 3-ACRYLAMIDOPYRAZOLE-5-CARBOXAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040082759-A1 | Process for preparing distamycin derivatives | PHARMACIA ITALIA S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| US-20040029810-A1 | Process for preparing distamycin derivatives | PHARMACIA ITALIA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| EP-1311481-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | Pharmacia Italia S.p.A. (IT) | 2003-05-21 | — | — | EP | disclosed |
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. | 2003-01-30 | — | — | US | disclosed |
| US-6482920-B1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA ITALIA, S.P.A. (IT) | 2002-11-19 | — | — | US | disclosed |
| US-6458768-B1 | ANTITUMOR AGENTS THAT CAN BE FORMULATED WITH A COMPOUND ALTERNATIVELY, CAN BE ADMINISTERED IN A MIXTURE OF DRUGS | PHARMACIA & UPJOHN, S.P.A. (IT) | 2002-10-01 | — | — | US | disclosed |
| WO-2002008184-A1 | PROCESS FOR PREPARING DISTAMYCIN DERIVATIVES | PHARMACIA ITALIA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| EP-0915845-B1 | ACRYLOYL SUBSTITUTED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-09-12 | — | — | EP | disclosed |
| EP-0912509-B1 | DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA & UPJOHN SPA (IT) | 2001-07-11 | — | — | EP | disclosed |
| US-6177408-B1 | COMPOUNDS SUCH AS 3-(1-METHYL-4(1-METHYL-4(1-METHYL-4(4-N,N-BIS(2 -CHLOROETHYL)AMINOCINNAMOYLAMIDO)PYRROLE-2-CARBOXAMIDO)PYRROLE-2 -CARBOXAMIDO)PYRROLE-2-CARBOXAMIDO)PROPIONAMIDINE | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-01-23 | — | — | US | disclosed |
| US-6165980-A | Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029810-A1 | Process for preparing distamycin derivatives | RPN2, DHPS, MYD88 | ESR1 3897/4885ESR2 3101/4885TOP1 168/4885 |
| US-20040082759-A1 | Process for preparing distamycin derivatives | GSTP1, GSTA1, GSS | ESR1 4086/4885ESR2 1721/4885TOP1 279/4885 |
| US-20030023031-A1 | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | EIF2AK2, ACR, EIF4A1 | ESR1 3985/4885ESR2 3455/4885TOP1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.